Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 8/20 | 0.55 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.39 |
| ▸ | XDH | P47989 | 2/20 | 0.37 |
| ▸ | CA12 | O43570 | 2/20 | 0.31 |
| ▸ | CA1 | P00915 | 2/20 | 0.31 |
| ▸ | CA2 | P00918 | 2/20 | 0.31 |
| ▸ | CA7 | P43166 | 2/20 | 0.31 |
| ▸ | CA9 | Q16790 | 2/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13998200 | 0.85 | HSP90AA1 (0.54) | HSP90AA1PTPN1XDHCA12CA1 | |
| SCHEMBL14010871 | 0.85 | HSP90AA1 (0.54) | HSP90AA1PTPN1XDHCA12CA1 | |
| SCHEMBL13998187 | 0.85 | HSP90AA1 (0.51) | HSP90AA1PTPN1XDHCA12CA1 | |
| Verproside SCHEMBL31619362 | 0.81 | HSP90AA1 (0.83) | HSP90AA1PTPN1XDH | |
| Verproside SCHEMBL2449966 | 0.81 | HSP90AA1 (0.83) | HSP90AA1PTPN1XDH | |
| Picroside Ii SCHEMBL29426003 | 0.73 | HSP90AA1 (0.78) | HSP90AA1XDH | |
| Picroside Ii SCHEMBL29425971 | 0.73 | HSP90AA1 (0.78) | HSP90AA1XDH | |
| Picroside Ii SCHEMBL30387354 | 0.73 | HSP90AA1 (0.78) | HSP90AA1XDH | |
| Picroside Ii SCHEMBL29367651 | 0.73 | HSP90AA1 (0.78) | HSP90AA1XDH | |
| SCHEMBL12013757 | 0.72 | HSP90AA1 (0.39) | HSP90AA1XDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080319042-A1 | Compositions and methods for treatment of liver disease | CALECO PHARMA CORP. | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080319042-A1 | Compositions and methods for treatment of liver disease | HCCS, HAVCR2, PYGL | HSP90AA1 3606/4885PTPN1 3880/4885XDH 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.